Chinese Journal of Chromatography ›› 2026, Vol. 44 ›› Issue (3): 248-256.DOI: 10.3724/SP.J.1123.2025.03017
• Articles • Previous Articles Next Articles
WANG Mo1,2, ZHANG Shunli1,2, ZHANG Rui1, SONG Yichuan1, SHI Jie1, XUE Qiaozhen1, HU Yanwei1,2,*(
)
Received:2025-04-07
Online:2026-03-08
Published:2026-03-12
CLC Number:
WANG Mo, ZHANG Shunli, ZHANG Rui, SONG Yichuan, SHI Jie, XUE Qiaozhen, HU Yanwei. Establishment and international comparison of reference methods for glycated hemoglobin[J]. Chinese Journal of Chromatography, 2026, 44(3): 248-256.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chrom-china.com/EN/10.3724/SP.J.1123.2025.03017
| Year | Study | Calibrators | Intercomparison samples | Controls | Others controls |
|---|---|---|---|---|---|
| 2018 | Chicago | pcal 2014-A, B, C, D, E, F | Chicago 01-Chicago 10 | LTCC-1, LTPC-1, Milano 8, Shanghai 1 | CalCheck 02 (2011-E) |
| 2019 | Barcelona | pcal 2016-A, B, C, D, E, F | Barcelona 01-Barcelona 10 | LTCC-1, LTPC-1, Chicago 1, Shanghai 8 | pcal 2012-D, pcal 2019-A, B,C,D,E, F |
| 2020 | Seoul | pcal 2016-A,B, C, D, E, F | Seoul 01-Seoul 10 | LTCC-1, LTPC-1, Chicago 1, Shanghai 8 | pcal 2019-B |
| 2022 | Kotten | pcal 2019-A,B, C, D, E,F | Kotten 01-Kotten 10 | LTCC-1, LTPC-1, Seoul 8, Chicago 1 | LTCC-2 |
| 2023 | Rome | pcal 2019-A, B, C, D, E, F | Rome 01- Rome 10 | LTPC-1, Seoul 8, Kotten 9 | LTCC-1, LTCC-2, pcal 2023-A, B, C, D, E,F |
| 2024 | Dubai | pcal 2023-A,B, C, D, E,F | Dubai 01-Dubai 10 | LTPC-1, LTPC-2, Kotten 9, Chicago 8 | LTCC-1, LTCC-2 |
Table 1 2018-2024 IFCC Glycated Hemoglobin International Comparison Sample Information
| Year | Study | Calibrators | Intercomparison samples | Controls | Others controls |
|---|---|---|---|---|---|
| 2018 | Chicago | pcal 2014-A, B, C, D, E, F | Chicago 01-Chicago 10 | LTCC-1, LTPC-1, Milano 8, Shanghai 1 | CalCheck 02 (2011-E) |
| 2019 | Barcelona | pcal 2016-A, B, C, D, E, F | Barcelona 01-Barcelona 10 | LTCC-1, LTPC-1, Chicago 1, Shanghai 8 | pcal 2012-D, pcal 2019-A, B,C,D,E, F |
| 2020 | Seoul | pcal 2016-A,B, C, D, E, F | Seoul 01-Seoul 10 | LTCC-1, LTPC-1, Chicago 1, Shanghai 8 | pcal 2019-B |
| 2022 | Kotten | pcal 2019-A,B, C, D, E,F | Kotten 01-Kotten 10 | LTCC-1, LTPC-1, Seoul 8, Chicago 1 | LTCC-2 |
| 2023 | Rome | pcal 2019-A, B, C, D, E, F | Rome 01- Rome 10 | LTPC-1, Seoul 8, Kotten 9 | LTCC-1, LTCC-2, pcal 2023-A, B, C, D, E,F |
| 2024 | Dubai | pcal 2023-A,B, C, D, E,F | Dubai 01-Dubai 10 | LTPC-1, LTPC-2, Kotten 9, Chicago 8 | LTCC-1, LTCC-2 |
| Item | Slope (m) | Intercept (b) | Correlation coefficient (r2) | Standard error of estimate (Syx) |
|---|---|---|---|---|
| Mean | 1.47 | -0.0001 | 0.9997 | 0.0013 |
| Range | 1.2550-1.5780 | -0.0011 | 0.9996-0.9998 | 0.0001-0.0019 |
Table 2 Linear regression of calibrator [HbA1c]/[HbA0] on peak area ratios of glycosylated hexapeptide and non glycosylated hexapeptide
| Item | Slope (m) | Intercept (b) | Correlation coefficient (r2) | Standard error of estimate (Syx) |
|---|---|---|---|---|
| Mean | 1.47 | -0.0001 | 0.9997 | 0.0013 |
| Range | 1.2550-1.5780 | -0.0011 | 0.9996-0.9998 | 0.0001-0.0019 |
| Control | Assigned value/(mmol/mol) | 2018 | 2019 | 2020 | |||
|---|---|---|---|---|---|---|---|
| Intra-assay CV/%(n=15) | Total CV/%(n=30) | Intra-assay CV/%(n=15) | Total CV/%(n=30) | Intra-assay CV/%(n=15) | Total CV/%(n=30) | ||
| LTCC-1 | 59.7 | 0.72, 1.21 | 1.23 | 0.63, 1.20 | 1.41 | 0.49, 1.05 | 1.31 |
| LTPC-1 | 49.9 | 1.10, 1.15 | 1.65 | 0.80, 0.93 | 1.36 | 0.38, 1.11 | 0.85 |
| LTPC-2 | 49.1 | / | / | / | / | / | / |
| Milano 8 | 78.8 | 0.98, 1.11 | 1.38 | / | / | / | / |
| Shanghai 1 | 31.4 | 0.69, 0.82 | 0.98 | / | / | / | / |
| Shanghai 8 | 78.3 | / | / | 0.50, 1.48 | 1.95 | 0.78, 1.29 | 1.94 |
| Chicago 1 | 31.9 | / | / | 0.73, 0.93 | 1.41 | 0.80, 1.62 | 1.79 |
| Chicago 8 | 78.6 | / | / | / | / | / | / |
| Seoul 8 | 81.6 | / | / | / | / | / | / |
| Kotten 9 | 31.2 | / | / | / | / | / | / |
Table 3 Intra-assay coefficients of variation (CVs) and the total CVs for the quantification of HbA1c
| Control | Assigned value/(mmol/mol) | 2018 | 2019 | 2020 | |||
|---|---|---|---|---|---|---|---|
| Intra-assay CV/%(n=15) | Total CV/%(n=30) | Intra-assay CV/%(n=15) | Total CV/%(n=30) | Intra-assay CV/%(n=15) | Total CV/%(n=30) | ||
| LTCC-1 | 59.7 | 0.72, 1.21 | 1.23 | 0.63, 1.20 | 1.41 | 0.49, 1.05 | 1.31 |
| LTPC-1 | 49.9 | 1.10, 1.15 | 1.65 | 0.80, 0.93 | 1.36 | 0.38, 1.11 | 0.85 |
| LTPC-2 | 49.1 | / | / | / | / | / | / |
| Milano 8 | 78.8 | 0.98, 1.11 | 1.38 | / | / | / | / |
| Shanghai 1 | 31.4 | 0.69, 0.82 | 0.98 | / | / | / | / |
| Shanghai 8 | 78.3 | / | / | 0.50, 1.48 | 1.95 | 0.78, 1.29 | 1.94 |
| Chicago 1 | 31.9 | / | / | 0.73, 0.93 | 1.41 | 0.80, 1.62 | 1.79 |
| Chicago 8 | 78.6 | / | / | / | / | / | / |
| Seoul 8 | 81.6 | / | / | / | / | / | / |
| Kotten 9 | 31.2 | / | / | / | / | / | / |
| Year | Systematic bias (abscissa) | Proportional bias (slope) | Combined statistical test outcome (Critical values a,b)* |
|---|---|---|---|
| 2018 | -0.16 | 0.016 | 1.5(10.1,5.1) |
| 1.27 | -0.018 | 3.0(10.4,5.1) | |
| 2019 | -0.22 | 0.009 | 0.4(5.8,2.8) |
| 0.48 | -0.006 | 0.4(6.1,3.0) | |
| 2020 | -0.29 | 0.008 | 0.3(5.8,2.8) |
| -0.26 | 0.008 | 0.3(6.0,3.0) | |
| 2022 | 0.34 | -0.009 | 0.4(5.8,2.9) |
| 0.58 | -0.006 | 0.6(5.9,2.9) | |
| 2023 | 0.30 | -0.006 | 0.2(5.7,2.9) |
| -0.45 | 0.021 | 2.4(5.5,2.7) | |
| 2024 | -0.69 | 0.011 | 0.9(5.7,2.9) |
| -0.15 | -0.002 | 0.1(5.5,2.7) |
Table 4 Bias and the results of the combined statistical test for the quantification of HbA1c
| Year | Systematic bias (abscissa) | Proportional bias (slope) | Combined statistical test outcome (Critical values a,b)* |
|---|---|---|---|
| 2018 | -0.16 | 0.016 | 1.5(10.1,5.1) |
| 1.27 | -0.018 | 3.0(10.4,5.1) | |
| 2019 | -0.22 | 0.009 | 0.4(5.8,2.8) |
| 0.48 | -0.006 | 0.4(6.1,3.0) | |
| 2020 | -0.29 | 0.008 | 0.3(5.8,2.8) |
| -0.26 | 0.008 | 0.3(6.0,3.0) | |
| 2022 | 0.34 | -0.009 | 0.4(5.8,2.9) |
| 0.58 | -0.006 | 0.6(5.9,2.9) | |
| 2023 | 0.30 | -0.006 | 0.2(5.7,2.9) |
| -0.45 | 0.021 | 2.4(5.5,2.7) | |
| 2024 | -0.69 | 0.011 | 0.9(5.7,2.9) |
| -0.15 | -0.002 | 0.1(5.5,2.7) |
| Samples | Target/(mmol/mol) | U*/(mmol/mol) |
|---|---|---|
| Kotten 9 | 31.2 | 0.96 |
| Seoul 8 | 81.6 | 2.33 |
| pcal-2019-E | 102.5 | 2.07 |
Table 5 Estimation of expanded uncertainties for the quantification of HbA1c
| Samples | Target/(mmol/mol) | U*/(mmol/mol) |
|---|---|---|
| Kotten 9 | 31.2 | 0.96 |
| Seoul 8 | 81.6 | 2.33 |
| pcal-2019-E | 102.5 | 2.07 |
|
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||